Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3475 publications

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Journal: JCO precision oncology
Published: October 16, 2025

Cutaneous vasculitis as a side effect of olaparib.

Cutaneous vasculitis as a side effect of olaparib.

Journal: JAAD case reports
Published: October 13, 2025

Olaparib Metabolism: Quantum Chemistry, Docking, and Dynamics-Based Insights into Mechanisms and Reactivity.

Olaparib Metabolism: Quantum Chemistry, Docking, and Dynamics-Based Insights into Mechanisms and Reactivity.

Journal: Chemical research in toxicology
Published: October 13, 2025

Lipophilicity-Optimized PARP-1 Tracers: Minimizing Hepatic Retention for Enhanced Target-to-Background PET Imaging.

Lipophilicity-Optimized PARP-1 Tracers: Minimizing Hepatic Retention for Enhanced Target-to-Background PET Imaging.

Journal: Molecular pharmaceutics
Published: October 08, 2025

Lymphocytic and Granulomatous Cutaneous Small Vessel Vasculitis Following PARP Inhibitor Therapy.

Lymphocytic and Granulomatous Cutaneous Small Vessel Vasculitis Following PARP Inhibitor Therapy.

Journal: Clinics in dermatology
Published: October 05, 2025

Prostate-Specific Membrane Antigen (PSMA)-Directed Dendrimer-Camptothecin Conjugate for Targeted Treatment of Prostate Cancer.

Prostate-Specific Membrane Antigen (PSMA)-Directed Dendrimer-Camptothecin Conjugate for Targeted Treatment of Prostate Cancer.

Journal: ACS applied nano materials
Published: October 01, 2025

Downregulated of CTGF reveals mechanism, remodels immune microenvironment, modulates drug sensitivity in bladder cancer.

Downregulated of CTGF reveals mechanism, remodels immune microenvironment, modulates drug sensitivity in bladder cancer.

Journal: Future science OA
Published: September 24, 2025

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).

Journal: JCO precision oncology
Published: September 16, 2025

Design, development, and therapeutic applications of PARP-1 selective inhibitors.

Design, development, and therapeutic applications of PARP-1 selective inhibitors.

Journal: Future medicinal chemistry
Published: September 15, 2025

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.

Journal: Research square
Published: September 15, 2025

The Discovery of RP-2119: A Potent, Selective, and Orally Bioavailable Polθ ATPase Inhibitor.

The Discovery of RP-2119: A Potent, Selective, and Orally Bioavailable Polθ ATPase Inhibitor.

Journal: Journal of medicinal chemistry
Published: September 08, 2025

Autophagy-dependent sensitization effects of PARP inhibitors on recurrent nasopharyngeal carcinoma treated with carbon ion and photon irradiation.

Autophagy-dependent sensitization effects of PARP inhibitors on recurrent nasopharyngeal carcinoma treated with carbon ion and photon irradiation.

Journal: Acta biochimica et biophysica Sinica
Published: September 02, 2025
Showing 1-12 of 3,475

Last Updated: 10/31/2025